Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.46 |
| ▸ | GRK2 | P25098 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | CASP8 | Q14790 | 1/20 | 0.44 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3389236 | 0.98 | RAPGEF4 (0.44) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL7793289 | 0.92 | TDP1 (0.49) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL14157500 | 0.92 | GRK2 (0.45) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL7790472 | 0.91 | RAB9A (0.45) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL3499884 | 0.90 | TDP1 (0.48) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| Hydrochloric Acid SCHEMBL14744193 | 0.90 | GRK2 (0.44) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL3323461 | 0.87 | ALDH1A1 (0.43) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL21460361 | 0.81 | HTR6 (0.46) | RAPGEF4 | |
| SCHEMBL28309969 | 0.79 | GRK2 (0.40) | RAPGEF4GRK2CASP6CASP8CTDSP1 | |
| SCHEMBL30775698 | 0.79 | LMNA (0.47) | GRK2CASP6CASP8CTDSP1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-114634483-B | Antimitotic amides for the treatment of cancer and proliferative diseases | 弗洛斯特生物科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| WO-2023064493-A1 | COMPOUNDS AND METHODS FOR TREATING CORONAVIRUSES | Clear Creek Bio, Inc. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-114634483-A | Antimitotic amides for the treatment of cancer and proliferative diseases | 弗洛斯特生物科技有限公司 | 2022-06-17 | — | — | CN | disclosed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC, INC. | 2022-01-13 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | FROST BIOLOGIC, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3107909-B1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | FROST BIOLOGIC INC (US) | 2021-07-14 | — | — | EP | disclosed |
| WO-2012141704-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-18 | — | — | WO | disclosed |
| EP-2491028-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | Boehringer Ingelheim International GmbH (DE) | 2012-08-29 | — | — | EP | disclosed |
| EP-2488526-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011049917-A1 | INDAZOLE AND PYRAZOLOPYRIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-04-28 | — | — | WO | disclosed |
| WO-2011047119-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-21 | — | — | WO | disclosed |
| EP-1565443-A4 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARM INC (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1751091-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | Elan Pharmaceuticals, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005095326-A2 | 2-AMINO- AND 2-THIO-SUBSTITUTED 1,3-DIAMINOPROPANES | ELAN PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | disclosed |
| EP-1565443-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | Elan Pharmaceuticals, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2004024081-A2 | ACETYL 2-HYDROXY-1,3 DIAMINOALKANES | ELAN PHARMACEUTICALS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220008395-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | CCNA1, CCNE1, CCNB1 | RAPGEF4 3783/4885GRK2 2454/4885CASP6 3283/4885 |
| US-20260034101-A1 | ANTIMITOTIC AMIDES FOR THE TREATMENT OF CANCER AND PROLIFERATIVE DISORDERS | NCOR1, NR0B1, NCOR2 | RAPGEF4 4721/4885GRK2 709/4885CASP6 2575/4885 |
| US-12383533-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | RAPGEF4 3783/4885GRK2 2454/4885CASP6 3283/4885 |
| US-11129813-B2 | Antimitotic amides for the treatment of cancer and proliferative disorders | CCNA1, CCNE1, CCNB1 | RAPGEF4 3783/4885GRK2 2454/4885CASP6 3283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.